Mr. Shaun Flanagan:

Just to be clear, it is not always just economics. Unmet need, the magnitude of the clinical evidence and all those things are factored into the drugs group decision. We have significant evidence, as I flagged before, that we often reimburse medicines, even when they do not satisfy conventional cost-effectiveness thresholds, as you might call them. Economics is not the only thing considered.